Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11900350rdf:typepubmed:Citationlld:pubmed
pubmed-article:11900350lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:11900350lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:11900350lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:11900350lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:11900350pubmed:issue5lld:pubmed
pubmed-article:11900350pubmed:dateCreated2002-3-19lld:pubmed
pubmed-article:11900350pubmed:abstractTextCepharanthine (12-O-methyl cepharanoline) is a plant alkaloid and has been shown to inhibit tumour necrosis factor-alpha- or phorbol 12-myristate 13-acetate-induced HIV-1 replication in the chronically infected promonocytic cell line, U1. Its mechanism of action is considered to be the inhibition of nuclear factor kappaB, a potent inducer of HIV-1 gene expression. In this study, we have synthesized 96 derivatives of cepharanoline, including cepharanthine, and examined their inhibitory effects on HIV-1 replication in U1 cells. Among the 12-O-alkyl derivatives, cepharanthine proved to be the most active, and the activity decreased as the length of the alkyl chain increased. All of the 12-O-acyl derivatives were totally inactive, while a few 12-O-carbamoyl derivatives displayed modest activity. Since 12-O-ethyl derivatives were found to be as active as cepharanthine against HIV-1 replication, we further synthesized various 12-O-ethyl derivatives of cepharanoline. Among the derivatives, five proved to be more active inhibitors than cepharanthine, and the most active compound was 12-O-ethylpiperazinyl cepharanoline. The 50% effective concentrations of this compound and cepharanthine were 0.0041 and 0.028 microg/ml (0.0060 and 0.046 microM), respectively.lld:pubmed
pubmed-article:11900350pubmed:languageenglld:pubmed
pubmed-article:11900350pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:citationSubsetIMlld:pubmed
pubmed-article:11900350pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11900350pubmed:statusMEDLINElld:pubmed
pubmed-article:11900350pubmed:monthSeplld:pubmed
pubmed-article:11900350pubmed:issn0956-3202lld:pubmed
pubmed-article:11900350pubmed:authorpubmed-author:OnoMMlld:pubmed
pubmed-article:11900350pubmed:authorpubmed-author:OkamotoMMlld:pubmed
pubmed-article:11900350pubmed:authorpubmed-author:BabbLLlld:pubmed
pubmed-article:11900350pubmed:authorpubmed-author:KashiwabaNNlld:pubmed
pubmed-article:11900350pubmed:issnTypePrintlld:pubmed
pubmed-article:11900350pubmed:volume12lld:pubmed
pubmed-article:11900350pubmed:ownerNLMlld:pubmed
pubmed-article:11900350pubmed:authorsCompleteYlld:pubmed
pubmed-article:11900350pubmed:pagination307-12lld:pubmed
pubmed-article:11900350pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:meshHeadingpubmed-meshheading:11900350...lld:pubmed
pubmed-article:11900350pubmed:year2001lld:pubmed
pubmed-article:11900350pubmed:articleTitleAnti-HIV-1 activity and structure-activity relationship of cepharanoline derivatives in chronically infected cells.lld:pubmed
pubmed-article:11900350pubmed:affiliationDivision of Human Retroviruses, Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Japan. baba@m.kufm.kagoshima-u.ac.jplld:pubmed
pubmed-article:11900350pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11900350pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11900350lld:pubmed